ArticleAJNR. American journal of neuroradiology2025
3D Quantified Morphologic Predictors of Intracranial Aneurysm Instability: A Longitudinal Study.
Article in AJNR. American journal of neuroradiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeThe performance of the current prediction models for intracranial aneurysm growth and rupture is suboptimal, and new markers are needed to improve prediction. There is a strong need for longitudinal studies that use standardized morphologic parameters. In this longitudinal study, we aimed to identify standardized 3D quantified morphologic parameters as predictors of aneurysm growth or rupture during long-term follow-up. MATERIALS AND
methodsWe used a database of consecutive patients with saccular unruptured intracranial aneurysms diagnosed between 2008 and 2018. Using a retrospective case-cohort design, we included a computer-generated random sample of aneurysms from the full cohort and aneurysms with growth or rupture during follow-up outside the random sample. The case-cohort design is efficient for low-incidence outcomes while maintaining the temporal association between exposure and outcome. Aneurysms were annotated on baseline CTA or MRA images, and 3D morphologic parameters were quantified. Univariable and multivariable Cox proportional hazards models were used to identify 3D morphologic predictors of either aneurysm growth or rupture. An inverse sampling probability weight was applied to obtain unbiased estimates of the hazard ratios.
resultsWe included 278 patients (median age, 59 years [interquartile range, 50-66]; 209 women) with 327 aneurysms, of which 239 aneurysms were stable during follow-up (73%), 68 grew without subsequent rupture (21%), 7 grew with subsequent rupture (2%), and 13 ruptured without preceding growth (4%). In the multivariable model for growth prediction (median follow-up, 4.1 years [interquartile range, 1.9-7.1]), major axis (hazard ratio, 1.16; 95% CI, 0.84-1.61) and shape index (hazard ratio, 1.53; 95% CI, 0.76-3.08) were retained, with a c-statistic of 0.56 (95% CI, 0.49-0.63). The same parameters were retained in the multivariable model for prediction of rupture (median follow-up, 4.5 years [interquartile range, 2.1-7.3]): major axis (hazard ratio, 2.27; 95% CI, 1.36-3.80) and shape index (hazard ratio, 3.33; 95% CI, 0.95-11.62), with a c-statistic of 0.85 (95% CI, 0.77-0.94).
conclusionsWe identified major axis and shape index as candidate 3D-quantified morphologic predictors of both aneurysm growth and rupture, but only for rupture did they demonstrate good discriminative power in our cohort. These parameters will need external validation and should be integrated with existing clinical prediction models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.